Bayer, Regeneron To Launch Phase III Trials Of Diabetes Eye Drug In Asia
This article was originally published in PharmAsia News
Executive Summary
Bayer HealthCare and Regeneron Pharmaceuticals plan joint Phase III trials of an eye treatment for diabetics in several Asian countries, including China and Russia.
Bayer HealthCare and Regeneron Pharmaceuticals plan joint Phase III trials of an eye treatment for diabetics in several Asian countries, including China and Russia. The drug is VEGF Trap-Eye (aflibercept) for treating macular edema in diabetes patients. The ailment is a leading cause of vision loss in adults under 50 years of age, particularly in China where only one other treatment is available. (Click here for more
)
"Bayer And Regeneron To Launch New Phase III Study For VEGF Trap-Eye" - Dow Jones (U.S.) (2/19/2013)